New marburg vaccine trial aims to stop deadly virus
NCT ID NCT06620003
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental vaccine against Marburg virus, a rare but severe disease. About 200 healthy adults will receive either the vaccine or a placebo to check for side effects and measure immune responses. The goal is to see if the vaccine is safe and prompts the body to fight the virus.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARBURG VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Optimal Research; LLC
Huntsville, Alabama, 35802, United States
-
Optimal Research; LLC
Melbourne, Florida, 32934, United States
-
Optimal Research; LLC
Peoria, Illinois, 61614, United States
-
Synexus Clinical Research US, Inc.
Phoenix, Arizona, 85020, United States
-
Synexus Clinical Research US, Inc.
Chicago, Illinois, 60602, United States
-
Synexus Clinical Research US, Inc.
San Antonio, Texas, 78229, United States
-
Synexus Clinical Research US; Inc.
Dallas, Texas, 75234, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.